通化东宝,600867,收入构成,报告日期,2021-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 注射用笔、血糖试纸、采血针等医疗器械,14807,8949,5858,39.57%,4.27% 中成药,4110,1567,2543,61.86%,1.85% 胰岛素类似物原料药及注射剂产,15875,1263,14612,92.04%,10.66% 塑钢窗及型材,33,31,2,7.41%,0% 商品房收入,2003,1280,723,36.09%,0.53% 人胰岛素原料药及注射剂产品,127991,15660,112331,87.76%,81.93% 其他(补充),1410,373,1037,73.54%,0.76% 通化东宝,600867,收入构成,报告日期,2020-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 注射用笔、血糖试纸、采血针等医疗器械,33396,20706,12690,38%,5.51% 重组人胰岛素注射剂产品系列,220654,26319,194335,88.07%,84.35% 重组人胰岛素原料药,5757,2654,3102,53.89%,1.35% 中成药,4946,1993,2953,59.71%,1.28% 塑钢窗及型材,682,531,151,22.18%,0.07% 其他(补充),3713,662,3051,82.17%,1.32% 丽景花园小区商品房,6893,4679,2213,32.11%,0.96% 技术服务,26,19,7,27.98%,0% 甘精胰岛素注射液,13150,1275,11875,90.31%,5.15% 通化东宝,600867,收入构成,报告日期,2020-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 注射用笔、血糖试纸、采血针等医疗器械,15870,9578,6292,39.65%,5.4% 重组人胰岛素原料药及注射剂产品,120841,18061,102780,85.05%,88.16% 中成药,1872,782,1090,58.24%,0.94% 胰岛素类似物(甘精胰岛素注射液),4051,403,3648,90.05%,3.13% 塑钢窗及型材,372,335,37,9.91%,0.03% 商品房收入,2267,1470,796,35.13%,0.68% 其他(补充),2182,254,1927,88.34%,1.65% 其他,26,19,7,27.98%,0.01% 通化东宝,600867,收入构成,报告日期,2019-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 商品房收入,11117,10041,1076,9.68%,0.52% 注射用笔、血糖试纸、采血针等医疗器械,35450,22736,12714,35.86%,6.18% 其他(补充),2470,634,1835,74.32%,0.89% 中成药,6762,3045,3718,54.98%,1.81% 重组人胰岛素原料药及注射剂产品,221430,35226,186203,84.09%,90.58% 塑钢窗及型材,486,469,17,3.55%,0.01% 通化东宝,600867,收入构成,报告日期,2018-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 注射用笔、血糖试纸、采血针等医疗器械,32610,22774,9836,30.16%,5.05% 塑钢窗及型材,958,862,96,10.02%,0.05% 重组人胰岛素原料药及注射剂产品,194084,25782,168302,86.72%,86.4% 商品房收入,31546,20758,10788,34.2%,5.54% 其他(补充),2676,776,1900,71.01%,0.98% 中成药,7418,3551,3867,52.14%,1.99% 通化东宝,600867,收入构成,报告日期,2017-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,7870,3394,4475,56.87%,2.35% 商品房收入,21426,15076,6349,29.63%,3.34% 重组人胰岛素原料药及注射剂产品,192137,21893,170243,88.61%,89.56% 塑钢窗及型材,4034,3158,876,21.71%,0.46% 注射用笔、血糖试纸、采血针等医疗器械,27167,20411,6756,24.87%,3.55% 其他(补充),1900,513,1387,73%,0.73% 通化东宝,600867,收入构成,报告日期,2016-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),3574,388,3186,89.13%,2.06% 房地产,6913,5157,1756,25.41%,1.13% 塑钢窗及型材,2609,2239,370,14.18%,0.24% 医疗器械,23288,17791,5497,23.6%,3.55% 中成药,7781,4090,3691,47.44%,2.38% 生物制品,159875,19520,140355,87.79%,90.64% 通化东宝,600867,收入构成,报告日期,2016-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他业务,706,62,644,91.15%,0.94% 塑钢窗及型材,569,603,-34,-5.99%,-0.05% 医疗及器械,11123,8789,2334,20.99%,3.4% 中成药,3770,1720,2050,54.37%,2.98% 生物制品,72877,9151,63726,87.44%,92.73% 通化东宝,600867,收入构成,报告日期,2015-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他品种及其他业务,1630,456,1174,72.01%,0.93% 甘舒霖笔、血糖仪等医疗器械,14998,13496,1502,10.02%,1.2% 东宝甘泰片,733,138,594,81.12%,0.47% 塑钢窗及型材,4576,4015,560,12.25%,0.45% 镇脑宁胶囊,7617,3353,4263,55.97%,3.39% 重组人胰岛素原料药及注射剂系列产品,137378,19833,117545,85.56%,93.56% 通化东宝,600867,收入构成,报告日期,2015-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),95,85,10,10.58%,0.02% 重组人胰岛素原料药及注射剂系列产品,63269,10197,53072,83.88%,95.23% 镇脑宁,4720,2074,2646,56.06%,4.75% 通化东宝,600867,收入构成,报告日期,2014-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 东宝甘泰片,1006,201,805,79.99%,0.81% 重组人胰岛素原料药及注射剂系列产品,112708,21303,91405,81.1%,91.47% 甘舒霖笔、血糖仪等医疗器械,14061,13837,224,1.59%,0.22% 其他品种及其他业务收入,1746,634,1112,63.69%,1.11% 塑钢窗及型材,7288,5525,1763,24.18%,1.76% 镇脑宁胶囊,8325,3704,4621,55.51%,4.62% 通化东宝,600867,收入构成,报告日期,2014-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 塑钢窗及型材,1297,941,356,27.46%,0.79% 甘舒霖笔、血糖仪等医疗器械,6666,6668,-2,-0.03%,-0% 镇脑宁,4316,1912,2404,55.7%,5.32% 其他品种,320,268,52,16.38%,0.12% 东宝甘泰,595,117,478,80.31%,1.06% 其他(补充),412,-- ,-- ,--,0% 重组人胰岛素原料药及注射剂系列产品,51962,10051,41911,80.66%,92.73% 通化东宝,600867,收入构成,报告日期,2013-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 甘舒霖笔、血糖仪等医疗器械,12871,12916,-45,-0.35%,-0.05% 塑钢窗及型材,7166,5576,1590,22.19%,1.94% 其他品种及其他业务,765,397,367,48.04%,0.45% 东宝甘泰片,1076,197,879,81.72%,1.07% 镇脑宁胶囊,8719,3758,4961,56.9%,6.06% 重组人胰岛素原料药及注射剂系列产品,89827,15698,74130,82.52%,90.53% 通化东宝,600867,收入构成,报告日期,2013-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),309,262,47,15.15%,0.13% 塑钢窗及型材,2170,1674,495,22.83%,1.34% 其他品种,185,136,48,26.18%,0.13% 甘舒霖笔、血糖仪等医疗器械,6589,7040,-450,-6.84%,-1.21% 东宝甘泰,613,114,499,81.45%,1.35% 镇脑宁胶囊,4526,1934,2592,57.27%,6.99% 重组人胰岛素原料药及注射剂,40776,6933,33843,83%,91.28% 通化东宝,600867,收入构成,报告日期,2012-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 甘舒霖笔、血糖仪等医疗器械,2503,3103,-600,-23.98%,-0.95% 其他品种及其他业务,1062,556,506,47.64%,0.8% 输液制品,-- ,-- ,-- ,--,0% 东宝甘泰片,1117,197,920,82.37%,1.45% 塑钢窗及型材,10172,8114,2058,20.23%,3.24% 镇脑宁胶囊,8177,2927,5250,64.2%,8.28% 重组人胰岛素原料药及注射剂系列产品,76121,20832,55289,72.63%,87.17% 通化东宝,600867,收入构成,报告日期,2012-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其中:关联交易,501,-- ,-- ,--,0% 其他品种,270,247,23,8.6%,0.08% 重组人胰岛素原料药及注射剂等,36052,11144,24908,69.09%,87.23% 塑钢窗及型材,2107,1760,347,16.45%,1.21% 其他(补充),123,14,108,88.21%,0.38% 东宝甘泰,621,109,512,82.44%,1.79% 镇脑宁胶囊,4154,1498,2657,63.95%,9.3% 通化东宝,600867,收入构成,报告日期,2011-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他品种,698,581,117,16.75%,0.24% 输液制品,25,36,-11,-43.8%,-0.02% 东宝甘泰片,896,166,730,81.44%,1.49% 塑钢窗及型材,8714,7345,1369,15.71%,2.8% 镇脑宁胶囊,7732,2763,4970,64.27%,10.16% 重组人胰岛素原料药及注射剂等,60384,18649,41736,69.12%,85.33% 通化东宝,600867,收入构成,报告日期,2011-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 塑钢窗及型材,1717,1144,573,33.37%,2.65% 其他品种,172,151,21,11.99%,0.1% 东宝甘泰,432,84,348,80.5%,1.61% 输液制品,15,21,-5,-33.91%,-0.02% 镇脑宁胶囊,3653,1312,2341,64.09%,10.84% 重组人胰岛素冻干粉及注射剂等,26949,8627,18322,67.99%,84.83% 通化东宝,600867,收入构成,报告日期,2010-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他品种,291,128,163,56.14%,0.41% 输液制品,388,504,-115,-29.75%,-0.29% 东宝甘泰片,904,154,750,82.95%,1.9% 镇脑宁,7264,2366,4897,67.42%,12.39% 重组人胰岛素原料药及注射剂等,49725,15908,33818,68.01%,85.59% 通化东宝,600867,收入构成,报告日期,2010-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他品种,186,156,30,16.06%,0.17% 塑钢窗及型材,1708,1803,-95,-5.53%,-0.55% 输液制品,277,364,-87,-31.21%,-0.5% 东宝甘泰,515,81,433,84.21%,2.52% 镇脑宁,3948,1250,2698,68.35%,15.72% 重组人胰岛素冻干粉及注射剂,22462,8278,14184,63.15%,82.64% 通化东宝,600867,收入构成,报告日期,2009-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他品种,919,617,301,32.78%,0.92% 塑钢窗及型材,6031,6270,-239,-3.96%,-0.73% 输液制品,2044,2331,-287,-14.05%,-0.87% 东宝甘泰片,1091,170,921,84.43%,2.8% 镇脑宁胶囊,7513,2256,5257,69.97%,16% 重组人胰岛素冻干粉及注射剂,39787,12873,26914,67.64%,81.89% 通化东宝,600867,收入构成,报告日期,2009-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,554,716,-163,-29.4%,-1.08% 塑钢窗,1490,1559,-70,-4.69%,-0.46% 东宝甘泰,639,98,541,84.69%,3.58% 输液制品,999,1185,-186,-18.65%,-1.23% 镇脑宁,4129,1143,2986,72.32%,19.78% 重组人胰岛素冻干粉及注射液,17957,5968,11989,66.76%,79.41% 通化东宝,600867,收入构成,报告日期,2008-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他品种,6349,6856,-507,-7.99%,-1.76% 塑钢窗及型材,10175,9401,774,7.61%,2.68% 输液制品,2696,2555,141,5.24%,0.49% 东宝甘泰片,1118,177,940,84.13%,3.25% 镇脑宁胶囊,7365,2059,5307,72.05%,18.37% 重组人胰岛素、冻干粉及注射液,27401,5167,22233,81.14%,76.96% 通化东宝,600867,收入构成,报告日期,2008-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 塑钢窗,3549,3213,336,9.48%,2.45% 镇脑宁,3698,1032,2666,72.09%,19.43% 重组人胰岛素冻干粉及注射液,13478,2759,10720,79.53%,78.12% 通化东宝,600867,收入构成,报告日期,2007-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 东宝甘泰,1286,204,1082,84.13%,5.09% 塑钢窗,10400,9861,539,5.18%,2.53% 输液制品,4176,2839,1337,32.01%,6.29% 镇脑宁胶囊,7186,1984,5202,72.39%,24.47% 基因重组人胰岛素冻干粉及注射液,16309,3211,13097,80.31%,61.62% 通化东宝,600867,收入构成,报告日期,2007-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,2027,2588,-561,-27.68%,-5.96% 塑钢窗,3703,3339,365,9.84%,3.87% 东宝甘泰,667,105,562,84.29%,5.97% 基因重组人胰岛素冻干粉及注射液,7077,1410,5667,80.08%,60.2% 输液制品,2107,1490,617,29.27%,6.55% 镇脑宁,3812,1047,2765,72.53%,29.37% 通化东宝,600867,收入构成,报告日期,2006-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 基因重组人胰岛素冻干粉及注射液,13332,3800,9532,71.49%,66.54% 镇脑宁,6718,1925,4792,71.34%,33.46% 通化东宝,600867,收入构成,报告日期,2006-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 塑钢门窗,7064,5309,1755,24.85%,14.57% 软袋输液制品,3512,2525,988,28.12%,8.2% 镇脑宁胶囊,4651,1349,3302,71%,27.41% 基因重组人胰岛素冻干粉及注射液,8710,2710,6000,68.88%,49.81% 通化东宝,600867,收入构成,报告日期,2006-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,947,809,138,14.53%,1.65% 塑钢窗,4336,3149,1187,27.38%,14.22% 东宝甘泰,512,103,409,79.87%,4.9% 基因重组人胰岛素冻干粉及注射液,5208,1521,3687,70.79%,44.17% 输液制品,2341,1598,743,31.74%,8.9% 镇脑宁,3002,818,2183,72.74%,26.16% 通化东宝,600867,收入构成,报告日期,2006-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 基因重组人胰岛素冻干粉及注射液,2486,867,1619,65.13%,60.77% 输液制品,1132,909,223,19.72%,8.38% 镇脑宁,1257,435,822,65.4%,30.85% 通化东宝,600867,收入构成,报告日期,2005-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 基因重组人胰岛素冻干粉及注射液,7035,2306,4729,67.23%,49.08% 镇脑宁,7274,2368,4906,67.45%,50.92% 通化东宝,600867,收入构成,报告日期,2005-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 塑钢门窗系列产品,6451,4857,1594,24.71%,20.52% 镇脑宁胶囊,4855,1519,3337,68.72%,42.95% 基因重组人胰岛素注射剂,2342,868,1474,62.95%,18.97% 基因重组人胰岛素冻干粉,2296,932,1364,59.41%,17.56% 通化东宝,600867,收入构成,报告日期,2005-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,902,579,323,35.83%,5.5% 塑钢窗,3830,2746,1084,28.31%,18.47% 基因重组人胰岛素注射剂(甘舒霖),1271,394,876,68.96%,14.92% 基因重组人胰岛素冻干粉,1749,747,1002,57.27%,17.07% 输液制品,1596,1761,-166,-10.39%,-2.82% 复方蛋氨酸胆碱片,831,187,643,77.46%,10.96% 镇脑宁胶囊,3073,966,2108,68.58%,35.9% 通化东宝,600867,收入构成,报告日期,2005-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 建材,721,462,260,36.02%,11.24% 药品,4107,2054,2052,49.97%,88.76% 通化东宝,600867,收入构成,报告日期,2004-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他药品,7657,0,7657,100%,43.12% 塑钢窗,13488,10060,3428,25.41%,19.31% 镇脑宁,9640,2970,6670,69.19%,37.57% 通化东宝,600867,收入构成,报告日期,2003-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 塑料建材,5529,3545,1984,35.88%,19.42% 生物制品,4148,1872,2276,54.88%,22.28% 中西成药,8862,2904,5958,67.23%,58.31% 通化东宝,600867,收入构成,报告日期,2003-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 生物制品,1292,680,612,47.4%,22.81% 中西成药,3031,958,2073,68.39%,77.19% 通化东宝,600867,收入构成,报告日期,2002-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 内部抵销,-426,-471,45,-10.6%,0.32% 铝塑,5510,3582,1928,34.99%,13.54% 塑钢,4391,3145,1246,28.38%,8.75% 制药,18581,7557,11024,59.33%,77.4%